• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

作者信息

Meyer Jens E, Brocks Carsten, Graefe Hendrik, Mala Carola, Thäns Natalie, Bürgle Markus, Rempel Annette, Rotter Nicole, Wollenberg Barbara, Lang Stephan

机构信息

Department of Otorhinolaryngology and Facial Plastic Surgery, University Hospital Schleswig Holstein - Campus Lübeck, Germany.

出版信息

Breast Care (Basel). 2008;3(s2):20-24. doi: 10.1159/000151736. Epub 2008 Oct 16.

DOI:10.1159/000151736
PMID:20824010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2930998/
Abstract
摘要

相似文献

1
The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.口服丝氨酸蛋白酶抑制剂WX-671——晚期头颈癌患者的首次体验
Breast Care (Basel). 2008;3(s2):20-24. doi: 10.1159/000151736. Epub 2008 Oct 16.
2
Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.动态对比增强磁共振成像中经水交换修正的动力学参数作为抗血管生成单药治疗晚期肝细胞癌生存预后生物标志物
PLoS One. 2015 Sep 14;10(9):e0136725. doi: 10.1371/journal.pone.0136725. eCollection 2015.
3
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.小型合成尿激酶抑制剂WX-UK1对大鼠乳腺癌转移的抑制作用及对原发性肿瘤生长的抑制作用。
Thromb Haemost. 2005 Apr;93(4):779-86. doi: 10.1160/TH04-11-0712.
4
Loss of heterozygosity in mammary serine protease inhibitor (maspin) and p53 at chromosome 17 and 18 in oral cavity squamous cell carcinoma.口腔鳞状细胞癌中17号和18号染色体上乳腺丝氨酸蛋白酶抑制剂（maspin）和p53的杂合性缺失
Head Neck. 2015 Sep;37(9):1239-45. doi: 10.1002/hed.23741. Epub 2014 Jul 10.
5
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.多模态治疗协同抑制肿瘤细胞侵袭和肿瘤诱导的血管生成。
BMC Cancer. 2010 Mar 11;10:92. doi: 10.1186/1471-2407-10-92.
6
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.百奥泰生物制药股份有限公司与高剂量顺铂放化疗联合治疗局部晚期高危头颈部鳞状细胞癌的随机、双盲、多中心、Ⅱ期临床研究。
Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3.
7
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.嵌合单克隆抗体G250用于晚期肾细胞癌患者的II期试验。
Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617.
8
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.一项在复发或转移性头颈部鳞状细胞癌患者中比较西妥昔单抗联合或不联合 PX-866（一种不可逆的口服磷脂酰肌醇 3-激酶抑制剂）的随机、Ⅱ期临床试验。
Ann Oncol. 2015 Mar;26(3):556-61. doi: 10.1093/annonc/mdu574. Epub 2014 Dec 18.
9
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.INGN 201：腺病毒载体p53、Ad5CMV-p53、腺病毒p53、p53基因疗法——英特洛根公司，RPR/INGN 201。
Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005.
10
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.随机对照试验比较手术和辅助放疗与同期放化疗治疗晚期局部非转移性头颈部鳞状细胞癌患者：10 年更新和亚组分析。
Cancer. 2015 May 15;121(10):1599-607. doi: 10.1002/cncr.29251. Epub 2015 Jan 29.

引用本文的文献

1
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment.乌帕司他联合吉西他滨治疗局部不可切除或转移性胰腺癌的Ⅰ期试验：安全性及初步疗效评估
Cancer Med. 2025 Jan;14(1):e70550. doi: 10.1002/cam4.70550.
2
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.丝氨酸蛋白酶尿激酶抑制剂乌帕司他和鞘氨醇激酶2抑制剂奥帕替尼对胆管癌患者来源异种移植瘤的联合抗肿瘤作用
Cancers (Basel). 2024 Mar 5;16(5):1050. doi: 10.3390/cancers16051050.
3
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).胰腺导管腺癌中的转移表型和免疫抑制肿瘤微环境：尿激酶型纤溶酶原激活物（PLAU）的关键作用。
Front Immunol. 2022 Dec 14;13:1060957. doi: 10.3389/fimmu.2022.1060957. eCollection 2022.
4
A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19.一项乌帕莫司他（一种宿主导向性丝氨酸蛋白酶抑制剂）用于 COVID-19 门诊治疗的随机、安慰剂对照的初步研究。
Int J Infect Dis. 2023 Mar;128:148-156. doi: 10.1016/j.ijid.2022.12.003. Epub 2022 Dec 19.
5
Trypsin inhibitor LH011 inhibited DSS-induced mice colitis alleviating inflammation and oxidative stress.胰蛋白酶抑制剂LH011可抑制葡聚糖硫酸钠（DSS）诱导的小鼠结肠炎，减轻炎症和氧化应激。
Front Pharmacol. 2022 Sep 27;13:986510. doi: 10.3389/fphar.2022.986510. eCollection 2022.
6
Role of Serine Proteases at the Tumor-Stroma Interface.丝氨酸蛋白酶在肿瘤-基质界面的作用。
Front Immunol. 2022 Feb 11;13:832418. doi: 10.3389/fimmu.2022.832418. eCollection 2022.
7
The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.纤溶酶原激活物-纤溶酶系统在生理性和病理性血管生成中的作用。
Int J Mol Sci. 2021 Dec 29;23(1):337. doi: 10.3390/ijms23010337.
8
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.纤维蛋白溶解系统与癌症：诊断与治疗应用。
Int J Mol Sci. 2021 Apr 22;22(9):4358. doi: 10.3390/ijms22094358.
9
Small Ones to Fight a Big Problem-Intervention of Cancer Metastasis by Small Molecules.小分子对抗大问题——小分子对癌症转移的干预
Cancers (Basel). 2020 Jun 3;12(6):1454. doi: 10.3390/cancers12061454.
10
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.尿激酶型纤溶酶原激活剂（uPA）及其受体（uPAR）的多方面作用：诊断、预后及治疗应用
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.

本文引用的文献

1
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.通过靶向尿激酶型纤溶酶原激活物受体抑制口腔癌的侵袭和转移
Oral Oncol. 2005 Nov;41(10):971-7. doi: 10.1016/j.oraloncology.2005.05.013. Epub 2005 Aug 29.
2
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.新型合成尿激酶型纤溶酶原激活剂系统抑制剂WX-UK1对癌细胞侵袭能力的抑制作用
Int J Cancer. 2004 Jul 20;110(6):815-24. doi: 10.1002/ijc.20192.
3
[Clinical and epidemiological data of patients with malignomas of the head and neck].[头颈部恶性肿瘤患者的临床和流行病学数据]
Laryngorhinootologie. 2002 Jul;81(7):499-508. doi: 10.1055/s-2002-33285.
4
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.干扰尿激酶纤溶酶原激活系统：一种有前景的实体瘤治疗理念。
Expert Opin Biol Ther. 2001 Jul;1(4):683-91. doi: 10.1517/14712598.1.4.683.
5
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.通过尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂鉴定的高危、淋巴结阴性乳腺癌患者的随机辅助化疗试验
J Natl Cancer Inst. 2001 Jun 20;93(12):913-20. doi: 10.1093/jnci/93.12.913.
6
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.尿激酶型纤溶酶原激活物、纤溶酶原激活物抑制剂1和组织蛋白酶D：它们在头颈部鳞状细胞癌中的预后意义分析
Anticancer Res. 2000 Sep-Oct;20(5C):3975-81.
7
The plasminogen activation system in tumor growth, invasion, and metastasis.肿瘤生长、侵袭和转移中的纤溶酶原激活系统。
Cell Mol Life Sci. 2000 Jan 20;57(1):25-40. doi: 10.1007/s000180050497.
8
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.尿激酶受体在头颈部鳞状细胞癌中的上调
Head Neck. 2000 Aug;22(5):498-504. doi: 10.1002/1097-0347(200008)22:5<498::aid-hed9>3.0.co;2-w.
9
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.头颈部鳞状细胞癌患者组织和血清中的尿激酶型纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂1型（PAI-1）
Eur J Cancer. 1998 Jul;34(8):1193-7. doi: 10.1016/s0959-8049(98)00029-x.
10
Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.纤溶酶原激活物和基质金属蛋白酶系统在表皮生长因子和分散因子刺激癌细胞侵袭中的作用。
Cancer Res. 1998 Nov 15;58(22):5221-30.